2 hours ago
1
Solskin
Cosmo Pharmaceuticals on Friday reported the renewal of its multi-year manufacturing and supply agreement with Takeda (NYSE:TAK), to produce Mesalazine MMX 1200 mg oral, once-daily treatment for ulcerative colitis.
Cosmo’s advanced manufacturing site in Lainate (Italy) is approved by multiple regulatory authorities
English (US) ·